Genomic Valley Biotech Open Offer: ₹30 Deal in 2026

Promoter stake sale triggers mandatory offer

Genomic Valley Biotech Limited has announced a mandatory open offer after a promoter agreed to sell a 46.06% stake in the company. The transaction was disclosed through a public announcement submitted to BSE on October 19, 2026. The offer is being made by Pankaj Grover and Abhisek Gupta under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Public shareholders can tender up to 7,94,170 equity shares under the offer. The offer price is ₹30 per equity share, payable in cash. The proposed acquisition marks a change in the company’s shareholding structure, with the acquirers set to obtain a substantial voting stake through a share purchase agreement.

Share purchase agreement signed on October 19

The triggering transaction is a share purchase agreement signed on October 19, 2026. Under the agreement, promoter seller Yogesh Agrawal has agreed to sell 14,07,000 equity shares to the acquirers. These shares represent 46.06% of Genomic Valley Biotech’s total voting share capital. The stated consideration for this stake purchase is ₹4.22 crore. The public announcement identifies the transaction as the event requiring an open offer to shareholders. Completion of the underlying share purchase agreement may take place before the completion of the open offer.

Acquirers to hold 46.06% after SPA purchase

Pankaj Grover and Abhisek Gupta had no shares in Genomic Valley Biotech before the proposed transaction, according to the disclosed offer details. Following acquisition of the promoter stake, Grover is expected to hold 29.69% of the voting share capital. Gupta is expected to hold 16.37%. Their combined holding would therefore stand at 46.06% after completion of the share purchase agreement. This level of ownership is the same as the stake proposed to be acquired from the promoter seller. The public offer gives eligible shareholders an opportunity to tender shares at the disclosed offer price.

Open offer covers 26% voting share capital

The open offer is for up to 7,94,170 equity shares, representing 26.00% of the total voting share capital of the company. At ₹30 per share, the maximum consideration payable if all shares are tendered and accepted is ₹2,38,25,100. This is equivalent to ₹2.38 crore. The offer will be paid in cash. It is not conditional on any minimum level of acceptance, as stated in the announcement. That means the offer process is not dependent on receiving tenders for a specified minimum number of shares.

Key transaction figures

Detailed public statement deadline

The detailed public statement, or DPS, is scheduled for publication in newspapers within five working days of the public announcement. The stated deadline is on or before October 27, 2026. The DPS is expected to provide further information on the offer’s financial arrangements, the acquirers’ background, statutory approvals and other terms. It will also set out the process relevant to shareholders who wish to participate in the offer. The public announcement is an initial disclosure, while the detailed public statement is intended to provide the fuller set of offer-related information required under the takeover regulations.

Why the offer is required under takeover rules

SEBI’s takeover regulations require an open offer when an acquisition crosses specified ownership or control thresholds in a listed company. In this case, the acquirers’ proposed combined holding of 46.06% follows their purchase of the promoter’s stake. The open offer is consequently being made for an additional 26% of the voting share capital. The requirement is designed to give public shareholders an exit opportunity when there is a substantial acquisition of shares or a potential change in control. The offer notice states that it is being made in compliance with Regulation 3(1) of the SEBI takeover regulations.

Company profile and operating context

Genomic Valley Biotech operates in biotechnology and healthcare solutions. The company describes its areas of experience as next-generation sequencing, oncology and artificial intelligence. Its shares are listed on BSE, where the company carries scrip code 539206. The available corporate-action information also states that the company recorded a 200% quarter-on-quarter jump in net profit over the preceding three months. No absolute profit figure was provided in the supplied information. Therefore, the disclosed growth rate indicates a reported change in quarterly profitability but does not establish the company’s revenue, earnings scale or valuation.

What shareholders should monitor

Shareholders will need to review the detailed public statement for the final offer timetable and tendering instructions. The DPS is also expected to explain the funding arrangements for the open offer and applicable statutory approvals. The disclosed ₹30 offer price and the maximum consideration of ₹2.38 crore apply to the announced offer size of 7,94,170 shares. Participation will depend on the terms and process set out in the offer documents. The company’s public announcement also notes that the share purchase agreement transaction may close before the open offer is completed.

Market relevance of the transaction

The transaction is important because it transfers a 46.06% promoter stake to new acquirers who previously held no shares in the company. It also initiates a formal offer process for public shareholders under SEBI rules. The stated acquisition value of ₹4.22 crore for the promoter stake and the ₹30 open-offer price are the principal financial terms disclosed so far. The detailed public statement is the next scheduled disclosure and is due on or before October 27, 2026. Its publication will provide the more complete regulatory and procedural record for investors assessing the offer.